Boardroom Alpha
10-Q primary document
KALA · Quarterly Report (Form 10-Q) · Filed May 15, 2026

Kala Bio Inc10-Q exhibit

kala-20260331xex10d6.htm

Exhibit 10.6

NOTE AMENDING AGREEMENT

THIS NOTE AMENDING AGREEMENT (this “Note Amending Agreement”) is dated as of May 11, 2026, by and between Minglemint Solutions LLC (the “Borrower”), and Kala Bio, Inc. or their assigns (the “Noteholder” and together with the Borrower, the Parties”).

WHEREAS, the Borrower is indebted to the Noteholder pursuant to a secured promissory note of the Borrower in the principal amount of US$7,000,000.00, dated February 9, 2026 (the “Note”);

AND WHEREAS, all capitalized terms used in this Note Amending Agreement which are not otherwise defined herein will have the meanings ascribed thereto in the Note;

AND WHEREAS, the Parties have agreed to amend the terms of the Note as detailed herein;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

1.

Article II of the Note is hereby amended by adding the following new Section 2.2 immediately after Section 2.01:

Section 2.02Noteholder's Right to Call the Loan. Notwithstanding Section 2.01 or any other provision of the Note, the Noteholder shall have the right, at any time and from time to time, to demand repayment of all or any portion of the outstanding principal amount of the Loan, together with all accrued and unpaid interest thereon and any other amounts owing under the Note in respect of the portion so called, by delivering written notice to the Borrower (a “Call Notice”). The Borrower shall repay the amount specified in the Call Notice within forty-five (45) days of the date of such Call Notice (the “Call Payment Date”). Any amount not repaid by the Call Payment Date shall bear interest at the Default Rate from and after the Call Payment Date until paid in full. For greater certainty, the Noteholder’s right to call the Loan pursuant to this Section 2.02 is in addition to, and shall not limit or prejudice, any other rights or remedies of the Noteholder under the Note or at law, including upon the occurrence of an Event of Default.”

2.

In all other respects, the terms and conditions of the Note shall remain unamended and in full force and effect.

3.

It is agreed and understood that this Note Amending Agreement may be executed by way of facsimile transmission and, further, may be executed in any number of counterparts, and all such counterparts shall, for all purposes, constitute one agreement binding on the Parties hereto, provided each Party has executed at least one counterpart, and shall be deemed to be an original notwithstanding that all Parties are not signatory to the same counterpart.

4.

This Note Amending Agreement shall be governed by, and construed in accordance with, the laws of the State of New York, without giving effect to principles of conflicts of law, as set out in Section 10.03 of the Note.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF the Parties have executed this Note Amending Agreement as of the date first above written.

v

MINGLEMINT SOLUTIONS LLC

Per:

/s/ Menachem Wagner

Authorized Signatory

KALA BIO, INC.

Per:

/s/ Avi Minkowitz

Authorized Signatory


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer